Pharmacodynamics Interview Questions & Answers
Best Pharmacodynamics Interview Questions and Answers
Dear Readers, Welcome to Pharmacodynamics Objective Questions and Answers have been designed specially to get you acquainted with the nature of questions you may encounter during your Job interview for the subject of Pharmacodynamics Multiple choice Questions. These Objective type Pharmacodynamics Questions are very important for campus placement test and job interviews. As per my experience good interviewers hardly plan to ask any particular question during your Job interview and these model questions are asked in the online technical test and interview of many Medical Industry.
1. Pharmacodynamics involves the study of following EXCEPT:
a) Biological and therapeutic effects of drugs
b) Absorption and distribution of drugs
c) Mechanisms of drug action
d) Drug interactions
2. Pharmacodynamics involves the study of following?
a) Mechanisms of drug action
b) Biotransformation of drugs in the organism
c) Distribution of drugs in the organism
d) Excretion of drug from the organism
3. Pharmacodynamics involves the following?
a) Information about main mechanisms of drug absorption
b) Information about unwanted effects
c) Information about biological barriers
d) Information about excretion of a drug from the organism
4. Pick out the answer which is the most appropriate to the term “receptor”
a) All types of ion channels modulated by a drug
b) Enzymes of oxidizing-reducing reactions activated by a drug
c) Active macromolecular components of a cell or an organism which a drug molecule has to combine with in order to elicit its specific effect
d) Carriers activated by a drug
5. What does “affinity” mean?
a) A measure of how tightly a drug binds to plasma proteins
b) A measure of how tightly a drug binds to a receptor
c) A measure of inhibiting potency of a drug
d) A measure of bioavailability of a drug
6. Target proteins which a drug molecule binds are:
a) Only receptors
b) Only ion channels
c) Only carriers
d) All of the above
7. An agonist is a substance that:
a) Interacts with the receptor without producing any effect
b) Interacts with the receptor and initiates changes in cell function, producing various effects
c) Increases concentration of another substance to produce effect
d) Interacts with plasma proteins and doesn’t produce any effect
8. If an agonist can produce maximal effects and has high efficacy it’s called:
a) Partial agonist
b) Antagonist
c) Agonist-antagonist
d) Full agonist
9. If an agonist can produce submaximal effects and has moderate efficacy it’s called:
a) Partial agonist
b) Antagonist
c) Agonist-antagonist
d) Full agonist
10. An antagonist is a substance that:
a) Binds to the receptors and initiates changes in cell function, producing maximal effect
b) Binds to the receptors and initiates changes in cell function, producing submaximal effect
c) Interacts with plasma proteins and doesn’t produce any effect
d) Binds to the receptors without directly altering their functions
11. A competitive antagonist is a substance that:
a) Interacts with receptors and produces submaximal effect
b) Binds to the same receptor site and progressively inhibits the agonist response
c) Binds to the nonspecific sites of tissue
d) Binds to one receptor subtype as an agonist and to another as an antagonist
12. The substance binding to one receptor subtype as an agonist and to another as an antagonist is called:
a) Competitive antagonist
b) Irreversible antagonist
c) Agonist-antagonist
d) Partial agonist
13. Irreversible interaction of an antagonist with a receptor is due to:
a) Ionic bonds
b) Hydrogen bonds
c) Covalent bonds
d) All of the above
14. Mechanisms of transmembrane signaling are the following EXCEPT:
a) Transmembrane receptors that bind and stimulate a protein tyrosine kinase
b) Gene replacement by the introduction of a therapeutic gene to correct a genetic effect
c) Ligand-gated ion channels that can be induced to open or close by binding a ligand
d) Transmembrane receptor protein that stimulates a GTP-binding signal transducer protein (G-protein) which in turn generates an intracellular second messenger
15. Tick the second messenger of G-protein-coupled (metabotropic) receptor:
a) Adenylyl cyclase
b) Sodium ions
c) Phospholipase C
d) cAMP
16. Tick the substance which changes the activity of an effector element but doesn’t belong to second messengers:
a) cAMP
b) cGMP
c) G–protein
d) Calcium ions
17. The increase of second messengers’ (cAMP, cGMP, Ca2+ etc.) concentration leads to:
a) Inhibition of intracellular protein kinases and protein phosphorylation
b) Proteinkinases activation and protein phosphorylation
c) Blocking of interaction between a receptor and an effector
d) Antagonism with endogenous ligands
18. Tick the substances whose mechanisms are based on interaction with ion channels
a) Sodium channel blockers
b) Calcium channel blockers
c) Potassium channels activators
d) All of the above
19. All of the following statements about efficacy and potency are true EXCEPT:
a) Efficacy is usually a more important clinical consideration than potency
b) Efficacy is the maximum effect of a drug
c) Potency is a comparative measure, refers to the different doses of two drugs that are needed to produce the same effect
d) The ED5 is a measure of drug’s efficacy
20. Give the definition for a therapeutical dose:
a) The amount of a substance to produce the minimal biological effect
b) The amount of a substance to produce effects hazardous for an organism
c) The amount of a substance to produce the required effect in most patients
d) The amount of a substance to accelerate an increase of concentration of medicine in an organism
21. Pick out the correct definition of a toxic dose:
a) The amount of substance to produce the minimal biological effect
b) The amount of substance to produce effects hazardous for an organism
c) The amount of substance to produce the necessary effect in most of patients
d) The amount of substance to fast creation of high concentration of medicine in an organism
22. Which effect may lead to toxic reactions when a drug is taken continuously or repeatedly?
a) Refractoriness
b) Cumulative effect
c) Tolerance
d) Tachyphylaxis
23. What term is used to describe a more gradual decrease in responsiveness to a drug, taking days or weeks to develop?
a) Refractoriness
b) Cumulative effect
c) Tolerance
d) Tachyphylaxis
24. What term is used to describe a decrease in responsiveness to a drug which develops in a few minutes?
a) Refractoriness
b) Cumulative effect
c) Tolerance
d) Tachyphylaxis
25. Tachyphylaxis is:
a) A drug interaction between two similar types of drugs
b) Very rapidly developing tolerance
c) A decrease in responsiveness to a drug, taking days or weeks to develop
d) None of the above
26. Drug resistance is a term used to describe the loss of effectiveness of antimicrobial or antitumour drugs. This consideration is:
a) True
b) False
27. Tolerance and drug resistance can be a consequence of:
a) Drug dependence
b) Increased metabolic degradation
c) Depressed renal drug excretion
d) Activation of a drug after hepatic first-pass
28. Tolerance and drug resistance can be a consequence of:
a) Change in receptors, loss of them or exhaustion of mediators
b) Increased receptor sensitivity
c) Decreased metabolic degradation
d) Decreased renal tubular secretion
29. Tolerance develops because of:
a) Diminished absorption
b) Rapid excretion of a drug
c) Both of the above
d) None of the above
30. Dependence is often associated with tolerance to a drug, a physical abstinence syndrome, and psychological dependence (craving). This consideration is:
a) True
b) False
31. The situation when failure to continue administering the drug results in serious psychological and somatic disturbances is called?
a) Tachyphylaxis
b) Sensibilization
c) Abstinence syndrome
d) Idiosyncrasy
32. What is the type of drug-to-drug interaction which is connected with processes of absorption, biotransformation, distribution and excretion?
a) Pharmacodynamic interaction
b) Physical and chemical interaction
c) Pharmaceutical interaction
d) Pharmacokinetic interaction
33. What is the type of drug-to-drug interaction which is the result of interaction at receptor, cell, enzyme or organ level?
a) Pharmacodynamic interaction
b) Physical and chemical interaction
c) Pharmaceutical interaction
d) Pharmacokinetic interaction
34. What phenomenon can occur in case of using a combination of drugs?
a) Tolerance
b) Tachyphylaxis
c) Accumulation
d) Synergism
35. If two drugs with the same effect, taken together, produce an effect that is equal in magnitude to the sum of the effects of the drugs given individually, it is called as:
a) Antagonism
b) Potentiation
c) Additive effect
d) None of the above
36. What does the term “potentiation” mean?
a) Cumulative ability of a drug
b) Hypersensitivity to a drug
c) Fast tolerance developing
d) Intensive increase of drug effects due to their combination
37. The types of antagonism are:
a) Summarized
b) Potentiated
c) Additive
d) Competitive
38. The term “chemical antagonism” means that:
a) two drugs combine with one another to form an inactive compound
b) two drugs combine with one another to form a more active compound
c) two drugs combine with one another to form a more water soluble compound
d) two drugs combine with one another to form a more fat soluble compound
39. A teratogenic action is:
a) Toxic action on the liver
b) Negative action on the fetus causing fetal malformation
c) Toxic action on blood system
d) Toxic action on kidneys
40. Characteristic unwanted reaction which isn’t related to a dose or to a pharmacodynamic property of a drug is called:
a) Idiosyncrasy
b) Hypersensitivity
c) Tolerance
d) Teratogenic action
41. Idiosyncratic reaction of a drug is:
a) A type of hypersensitivity reaction
b) A type of drug antagonism
c) Unpredictable, inherent, qualitatively abnormal reaction to a drug
d) Quantitatively exaggerated response
42. Therapeutic index (TI) is:
a) A ratio used to evaluate the safety and usefulness of a drug for indication
b) A ratio used to evaluate the effectiveness of a drug
c) A ratio used to evaluate the bioavailability of a drug
d) A ratio used to evaluate the elimination of a drug